Harmony Biosciences
As of the edition of 20 October 2026, Harmony Biosciences runs 2 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Status not established | 1 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Pitolisant | Ends 2033 (exclusivity) | 0 |
A route B row is one company at one target.
Where its trials are
- Nervous system: 2 trials led
- Inherited and neonatal: 1 trials led
- Mental health: 1 trials led